Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,817 | $24,798 | $34,333 | $19,883 |
| G&A Expenses | $7,701 | $7,220 | $7,455 | $6,754 |
| SG&A Expenses | $7,701 | $7,220 | $7,455 | $6,754 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $27,158 | $0 | $0 | $0 |
| Operating Expenses | $40,676 | $32,018 | $41,788 | $26,637 |
| Operating Income | -$40,676 | -$32,018 | -$41,788 | -$26,637 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,386 | $4,682 | $5,014 | $5,866 |
| Pre-Tax Income | -$36,290 | -$27,336 | -$36,774 | -$20,771 |
| Tax Expense | $40 | $52 | $72 | $186 |
| Net Income | -$36,330 | -$27,388 | -$36,846 | -$20,957 |
| % Margin | – | – | – | – |
| EPS | -0.67 | -0.5 | -0.68 | -0.38 |
| % Growth | -34% | 26.5% | -78.9% | – |
| EPS Diluted | -0.67 | -0.5 | -0.68 | -0.38 |
| Weighted Avg Shares Out | 54,564 | 54,539 | 54,457 | 54,440 |
| Weighted Avg Shares Out Dil | 54,564 | 54,539 | 54,457 | 54,440 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,386 | $4,682 | $5,014 | $5,866 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $56 | $19 | $19 | $15 |
| EBITDA | -$36,234 | -$31,999 | -$41,769 | -$26,622 |
| % Margin | – | – | – | – |